| Autor: |
Rubio-Viqueira, Belen, Tarruella, Margarita Majem, Lázaro, Martín, Estévez, Sergio Vázquez, Córdoba-Ortega, Juan Felipe, Maiques, Inmaculada Maestu, González, Jorge García, Cordellat, Ana Blasco, Valdivia-Bautista, Javier, Arenas, Carmen González, Sánchez Torres, Jose Miguel |
| Zdroj: |
Lung Cancer Management; December 2021, Vol. 10 Issue: 4 |
| Abstrakt: |
Aim:To describe the clinical management and PD-L1 testing of patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC) without driver mutations in Spain. Methods:Multicenter, retrospective study. Results:Among 297 evaluated patients, 89.2% received systemic treatment for stage IV disease, of whom 53.6% received platinum doublet therapy, 26.8% immunotherapy as monotherapy and 14.7% immunotherapy + chemotherapy, with 9.4% receiving treatment as part of a clinical trial. Treatment was initiated 1 month after histological diagnosis, with PD-L1 test results available in most cases (92.6%). PD-L1 testing was performed in 287 patients, 95.1% by in-house tests, mostly with the 22C3 pharmDx assay. The factor most strongly associated with treatment selection was, as expected, the expression of PD-L1. Conclusion:PD-L1 testing is implemented in clinical practice and seems to guide treatment decisions in patients with NSCLC in Spain. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
